Manuscripts

Search by keyword, year, or author name.

Showing 1543 manuscripts.

HIV drug development: the next 25 years

Charles Flexner. HIV drug development: the next 25 years. Nature Reviews Drug Discovery. 2007. 6: 959-66.

Year

2007

Journal

Nature Reviews Drug Discovery

Hidden Markov models for settings with interval-censored transition times and uncertain time origin: application to HIV genetic analyses

B. Healy, Victor DeGruttola. Hidden Markov models for settings with interval-censored transition times and uncertain time origin: application to HIV genetic analyses. Biostatistics. 2007. 8: 438-52.

Year

2007

Journal

Biostatistics

Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations

Roger Paredes, Vincent C. Marconi, Thomas B. Campbell, Daniel R. Kuritzkes. Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations. Journal of Virological Methods. 2007. 146: 136-46.

Year

2007

Journal

Journal of Virological Methods

A comparison of three initial antiretroviral AIDS regimens

Heather Ribaudo, Daniel R. Kuritzkes, Roy (Trip) Gulick. A comparison of three initial antiretroviral AIDS regimens. New England Journal of Medicine. 2007. 357: 1056-7.

Year

2007

Journal

New England Journal of Medicine

When and how can endpoints be changed after initiation of a randomized clinical trial?

Scott Evans. When and how can endpoints be changed after initiation of a randomized clinical trial?. Public Library of Science Clinical Trials. 2007. 2: e18.

Year

2007

Journal

Public Library of Science Clinical Trials

Minorities, the poor and survivors of abuse: HIV-infected patients in the US deep south

Brian Wells Pence, Susan Reif, Kathryn Whetten, Jane Leserman, Dalene Stangl, Marvin Swartz, Nathan Thielman, Michael J. Mugavero. Minorities, the poor and survivors of abuse: HIV-infected patients in the US deep south. Journal of the Southern Medical Association. 2007. 100: 1114-22.

Year

2007

Journal

Journal of the Southern Medical Association

Predicting CD4 lymphocyte count <200 cells/mm3 in an HIV type 1-infected African population

Susan C. Morpeth, John A. Crump, Humphrey J. Shao, Habib O. Ramadhani, Peter R. Kisenge, Cindy A. Moylan, Susanna Naggie, L. Brett Caram, Keren Z. Landman, Noel E. Sam, Dafrosa K. Itemba, John F. Shao, John Alexander Bartlett, Nathan Thielman. Predicting CD4 lymphocyte count <200 cells/mm3 in an HIV type 1-infected African population. AIDS Research and Human Retroviruses. 2007. 23: 1230-6.

Year

2007

Journal

AIDS Research and Human Retroviruses

Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study

Sharon L. Shriver, Linda L. Millar, Giovanni Schifitto, Dodi Colquhoun, Bradford A. Navia, Robert Lenkinski, Constantin Yiannoutsos, R.Gilberto Gonzalez, Christina M. Marra, Stuart A. Lipton, Linda Chang, Thomas Ernst, Jeffrey G. Jarvik, Eric N. Miller, Elyse J. Singer, Ronald J. Ellis, Dennis Kolson, David M. Simpson, Avindra Nath, Joseph R. Berger. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS. 2007. 21: 1877-86.

Year

2007

Journal

AIDS

Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359

Richard H. Haubrich, Hongyu Jiang, Ronald Swanstrom, Michael P. Bates, David Katzenstein, Leslie A. Petch, Courtney V. Fletcher, Susan A. Fiscus, Roy (Trip) Gulick. Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359. HIV Clinical Trials. 2007. 8: 63-7.

Year

2007

Journal

HIV Clinical Trials

Effect of antiretroviral therapy and hepatitis C co-infection on changes in lipid levels in HIV-infected patients 48 weeks after initiation of therapy

Jack T. Stapleton, Kara Bennett, Ronald J. Bosch, Philip M. Polgreen, Susan Swindells. Effect of antiretroviral therapy and hepatitis C co-infection on changes in lipid levels in HIV-infected patients 48 weeks after initiation of therapy. HIV Clinical Trials. 2007. 8: 429-36.

Year

2007

Journal

HIV Clinical Trials